These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1761450)

  • 41. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
    Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
    [No Abstract]   [Full Text] [Related]  

  • 42. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
    Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
    Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Aminoglycosides in patients with mucoviscidosis and pulmonary exacerbation. Comparison of once or three times daily administration].
    Heininger U; Böwing B; Stehr K; Solbach W
    Klin Padiatr; 1993; 205(1):18-22. PubMed ID: 8445848
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tobramycin dosing in cystic fibrosis.
    Smyth A; Touw D; Tan KH; Bertenshaw C; Stableforth D
    Lancet; 2005 May 21-27; 365(9473):1767-8. PubMed ID: 15910946
    [No Abstract]   [Full Text] [Related]  

  • 46. Bayesian Forecasting for Intravenous Tobramycin Dosing in Adults With Cystic Fibrosis Using One Versus Two Serum Concentrations in a Dosing Interval.
    Drennan PG; Thoma Y; Barry L; Matthey J; Sivam S; van Hal SJ
    Ther Drug Monit; 2021 Aug; 43(4):505-511. PubMed ID: 33941739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical use and toxicity of high-dose tobramycin in patients with pseudomonal endocarditis.
    Rybak MJ; Boike SC; Levine DP; Erickson SR
    J Antimicrob Chemother; 1986 Jan; 17(1):115-20. PubMed ID: 3949634
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Personalized tobramycin dosing in children with cystic fibrosis: a comparative clinical evaluation of log-linear and Bayesian methods.
    Imani S; Fitzgerald DA; Robinson PD; Selvadurai H; Sandaradura I; Lai T
    J Antimicrob Chemother; 2022 Nov; 77(12):3358-3366. PubMed ID: 36172897
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
    Lam W; Tjon J; Seto W; Dekker A; Wong C; Atenafu E; Bitnun A; Waters V; Yau Y; Solomon M; Ratjen F
    J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients.
    Rubio TT; Shapiro C
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():147-52. PubMed ID: 3100490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
    Bilton D; Henig N; Morrissey B; Gotfried M
    Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tobramycin elimination rate change from first to later doses in older cystic fibrosis patients.
    Horner GW; Stempel DA
    Drug Intell Clin Pharm; 1987 Mar; 21(3):276-8. PubMed ID: 3569027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
    Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
    Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.
    Dong M; Rodriguez AV; Blankenship CA; McPhail G; Vinks AA; Hunter LL
    J Antimicrob Chemother; 2021 Oct; 76(11):2923-2931. PubMed ID: 34379758
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Necessity of Tobramycin trough Levels in Once Daily Iv-Treatment in Patients with Cystic Fibrosis.
    Schlegtendal A; Rettberg S; Maier C; Brinkmann F; Koerner-Rettberg C
    Klin Padiatr; 2024 Feb; 236(2):116-122. PubMed ID: 38286409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tobramycin and carbenicillin compared with gentamicin and carbenicillin in the treatment of infection with Pseudomonas aeruginosa in adult patients with cystic fibrosis.
    Hodson ME; Wingfield HJ; Batten JC
    Br J Dis Chest; 1983 Jan; 77(1):71-7. PubMed ID: 6407508
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
    Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
    Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
    Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients.
    Govoni M; Poli G; Acerbi D; Santoro D; Cicirello H; Annoni O; Ružička J
    Pulm Pharmacol Ther; 2013 Apr; 26(2):249-55. PubMed ID: 23232039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.